Erythropoiesis-Stimulating Agents: Creation and Validation of a Computerized Prescriber Order Entry Alert

Abstract

Get full access to this article

View all access options for this article.

References

Drueke

Locatelli

Clyne

. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071–84.

Besarab

Bolton

Browne

. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584–90.

Henke

Laszig

Rube

. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255–60.

Leyland-Jones

Smeiglazov

Pawlicki

. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960–72.

Smith

Aapro

Ludwig

. Darbepoetin alfa for the treatment of anemia in patients with active cancer but not receiving active chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008;26:1040–50.

Corwin

Gettinger

Fabian

. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007;357:965–76.

Food and Drug Administration. Information for healthcare professionals, erythropoiesis stimulating agents (ESA). www.fda.gov/cder/drug/infosheets/HCP/rhe20hcp.htm (accessed 2007 Jul 31).